Syngene International has announced a strategic collaboration with John Hopkins University, MD, US, to advance early?stage drug discovery programmes and platform technologies emerging from the university’s research labs.

The collaboration will be delivered by Syngene SynVent, a fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology and early development.

Kenneth Barr, Senior Vice President, Head—Strategic Collaborations, Syngene International, said, “We are delighted to be working with a renowned institution like Johns Hopkins. We are uniquely positioned to translate pioneering research into credible therapeutic candidates, and our goal is to significantly compress the time required for high?potential programmes to become clinically relevant, creating a faster and more efficient pipeline of new medicines.”

Syngene’s Connector model, which is designed to bridge high-potential, early-stage assets and technology platforms with strategic investors and downstream partnerships, will be leveraged to bring together relevant stakeholders to sponsor research and secure licensing options for the resulting Intellectual Property (IP).

According to Paul Nkansah, Senior Director—Corporate Partnerships, Johns Hopkins Technology Ventures, this novel collaboration model has the potential to link discoveries from Johns Hopkins laboratories with the drug discovery capabilities of Syngene, pharmaceutical and biotech partners and investors–accelerating ground-breaking innovations developed at Johns Hopkins and turning promising science into credible development programmes that could ultimately lead to new options for patients.